Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call Transcript March 10, 2025Fennec Pharmaceuticals Inc. misses on earnings expectations.
Fennec Pharmaceuticals Inc. (FENC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Southpoint Capital Advisors John Smith Clark | 4,077,214 | $25,767,992 | 0.6% | |
| 2. | Solas Capital Management Frederick Tucker Golden | 2,250,919 | $14,225,808 | +18% | 9.44% |
| 3. | DG Capital Management Dov Gertzulin | 1,114,692 | $7,044,853 | -27% | 2.36% |
| 4. | Harbert Management Raymond J. Harbert | 466,869 | $2,950,612 | 1.53% | |
| 5. | Tontine Asset Management Jeffrey Gendell | 199,275 | $1,259,418 | -15% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 12,500 | 104,271 | 2024-04-01 | Filing | ||
| $0.00 | 29,167 | 316,638 | 2024-04-01 | Filing | ||
| $6.25 | 80,000 | Large Shareholder | 4,077,214 | 2020-05-04 | Filing | |
| $6.25 | 768,000 | Large Shareholder | 3,993,694 | 2020-04-30 | Filing | |
| $10.23 | 2,000 | Large Shareholder | 1,674,614 | 2017-10-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.25 | 10,000 | 61,156 | 2025-04-04 | Filing | ||
| $6.79 | 10,000 | 68,725 | 2025-03-05 | Filing | ||
| $6.82 | 1,186 | 53,020 | 2025-02-14 | Filing | ||
| $6.66 | 10,000 | 76,294 | 2025-02-05 | Filing | ||
| $6.08 | 7,569 | 83,863 | 2025-01-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 33,364 | $203,178 | 0% | |
| 2. | 982 | $5,980 | 0% | |
| 3. | 110 | $670 | 0% |
News See All
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Call Transcript August 13, 2024Fennec Pharmaceuticals Inc. misses on earnings expectations.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' First Quarter 2024 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' Fourth Quarter and Full Year 2023 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2023 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to the Fennec Pharmaceuticals Second Quarter 2023 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals First Quarter 2023 Earnings and Corporate Update Conference Call.
Top 5 Stock Picks of Lawrence Kam's Sonic Capital
In this article, we will take a look at the top 5 stock picks of Lawrence Kam's Sonic Capital.
Hedge Funds Are Piling Into Fennec Pharmaceuticals Inc. (FENC)
In this article you are going to find out whether hedge funds think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a good investment right now.
Billionaire Hedge Funds
